↓ Skip to main content

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.

Overview of attention for article published in Cancer Discovery, November 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
14 news outlets
blogs
1 blog
twitter
22 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
3 Mendeley